BAKX Therapeutics

United States - New York | Boston

• 18/11/2021
• Series A
• $25,000,000

We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations

We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis

We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients

Related People

Sree KantFounder

United States - New York, New York

Life Sciences thought leader and executive. Former head of Corporate Development at Life Biosciences; Former head of partnering strategy for Pfizer. Former healthcare principal at Boston Consulting.

LinkedIn https://www.linkedin.com/in/sreekant/